CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it has been added to the Russell 3000® and Russell 2000® Indices as part of Russell Investments' first quarter 2014 IPO additions.
Help employers find you! Check out all the jobs and post your resume.
